Robert Leboyer

Robert LeBoyer is a seasoned professional in the biotechnology sector, currently serving as a Senior Biotechnology Analyst at NOBLE Capital Markets since April 2021. Previous roles include Managing Director and Biotechnology Analyst positions at Ladenburg Thalmann and ROTH Capital Partners, along with various analytical and leadership positions in firms such as Aegis Capital, Maxim Group, and Aurora Capital Group. With a background that includes serving as Chief Financial Officer at SignPath Pharmaceuticals, Robert has extensive experience in equity research and investment banking. An alumnus of Columbia Business School with an MBA in Finance and Operations Management and a Bachelor's degree in Economics from Tulane University, Robert possesses a strong educational foundation that complements a robust career trajectory in biotechnology analysis.